Islet Cell Transplant with Lantidra: First Successful Procedure

This ⁤text describes⁢ Lantidra, a new treatment for a more severe form of type 1 diabetes, developed through research at the University of Illinois Chicago (UIC) and clinical trials at UI Health. Here’s a breakdown:

Lantidra: A new ⁢treatment for a severe form of type 1 diabetes.
Type 1 Diabetes Severity: The text‍ highlights the serious complications of this⁢ severe form, including blindness, kidney ⁣failure, limb amputation, stroke, and heart attack.
UI Health’s Role: UI Health partners with patients and their insurance to get coverage for Lantidra.
Advancement Origin: Lantidra was⁣ developed through research at UIC by⁤ Dr. José Oberholzer. Clinical Trials: Clinical trials supporting Lantidra were ‍conducted at UI Health.
Commercialization: The⁤ clinical data was⁤ licensed to CellTrans⁤ Inc.,⁣ founded by Dr. oberholzer, for FDA ⁢approval and therapy development.
* ⁤ Source: The ⁣information is‍ provided by ⁣the University of Illinois at Chicago.